Samuel Rosner is an Oncology physician affiliated with University of Maryland, Baltimore. OpenAlex indexes 143 publications with 3,363 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
22 S Greene St Fl 1
Baltimore, MD 212011590
Telephone
410-328-2575Provider last certified this registry record 24 Oct 2023.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- AstraZeneca UK LimitedProgram year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
47.4%Phenothiazine26.3%Prochlorperazine Maleate100%Part D≥18 patientsAtypical Antipsychotic11.4%Olanzapine Odt100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
26.3%Serotonin-3 Receptor Antagonist15.8%Ondansetron Hcl100%Part D≥16 patientsCorticosteroid10.5%Prednisone100%Part D<11 patientsCancer & immunology
15.8%Kinase inhibitor15.8%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
PubMed
2024 - Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Clinical Cancer Research
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Kittner
University of Maryland, Baltimore
Edward Sausville, MD
University of Maryland, Baltimore
Aloke Finn, MD
University of Maryland, Baltimore
Christopher Plowe, MD
University of Maryland, Baltimore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”